Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence

The treatment of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis (TB) remains a challenge for clinicians for several reasons, including the large number of drugs required, the cost, the tolerability of single drugs and their combinations, and the effectiveness and long tre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The European respiratory journal 2017-11, Vol.50 (5), p.1701462-1701462
Hauptverfasser:	Pontali, Emanuele, Sotgiu, Giovanni, Tiberi, Simon, D'Ambrosio, Lia, Centis, Rosella, Migliori, Giovanni B
Format:	Artikel
Sprache:	eng
Schlagworte:	Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects Diarylquinolines - administration & dosage Diarylquinolines - adverse effects Electrocardiography Heart diseases Humans Long QT Syndrome - chemically induced Long QT Syndrome - diagnosis Multidrug resistance Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The treatment of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis (TB) remains a challenge for clinicians for several reasons, including the large number of drugs required, the cost, the tolerability of single drugs and their combinations, and the effectiveness and long treatment duration [1–6]. Therefore, fresh attention has recently been paid to new and repurposed anti-TB drugs [4, 5, 7–18].
ISSN:	0903-1936 1399-3003
DOI:	10.1183/13993003.01462-2017